Mekinist 2 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FXSA0
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,191
Award facts
- Contract value 100% obligated
- $10,191.22 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $10,191.22 delivery order to AmerisourceBergen Drug Corp on December 30, 2025, for the supply of Mekinist 2 mg tablets (30-count units). This competitively awarded, firm fixed-price contract is categorized as a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of January 22, 2026. Mekinist is a targeted cancer therapy medication, indicating this procurement supports the military health system's oncology pharmaceutical supply chain.
This delivery order exemplifies AmerisourceBergen's role as a critical pharmaceutical distributor within the federal medical supply network, particularly for military and veteran healthcare systems. As the primary vendor under the DLA Troop Support Medical Pharmaceutical Prime Vendor Global Program, the company maintains a comprehensive portfolio of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. The award reflects the company's competitive capability to fulfill federal procurement requirements through open competition, with no set-aside designation applied. AmerisourceBergen's ongoing partnership with DLA enables flexible sourcing of specialized oncology medications and other critical pharmaceuticals essential to Defense Health Agency operations and broader military healthcare support worldwide.
Quick answers
Who was awarded contract SPE2DR26FXSA0?
SPE2DR26FXSA0 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 30, 2025.
How much is contract SPE2DR26FXSA0 worth?
The government has obligated $10,191 on SPE2DR26FXSA0.
Is contract SPE2DR26FXSA0 an order under another contract?
Yes. SPE2DR26FXSA0 is a delivery order under SPE2DR25D3004, an indefinite delivery contract.
Was contract SPE2DR26FXSA0 competed?
The extent of competition for SPE2DR26FXSA0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award